Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
13 októbra, 2020 5:56 pmAuthor(s): Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, et al. Abstract: S801 Session topic: 21. Aggressive Non-Hodgkin...
AN UPDATED ANALYSIS OF JULIET, A GLOBAL PIVOTAL PHASE 2 TRIAL OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
13 októbra, 2020 5:56 pmAuthor(s): Peter Borchmann, Constantine S. Tam, Ulrich Jäger Abstract: S799 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical...
RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
13 októbra, 2020 5:56 pmAuthor(s): Frank Morschhauser, Nathan H. Fowler, Pierre Feugier, et. al Abstract: S154 Session topic: 20. Indolent Non-Hodgkin lymphoma...
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
13 októbra, 2020 5:56 pmAuthor(s): Laurie H. Sehn, Manali Kamdar, Alex F. Herrera, et al. Abstract: S802 Session topic: 21. Aggressive Non-Hodgkin...
FINAL ANALYSIS OF THE AHL201 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA
13 októbra, 2020 5:56 pmAuthor(s): Olivier Casasnovas, Pauline Brice, Reda Bouabdallah, et. al Abstract: S110 Session topic: 17. Hodgkin lymphoma – Clinical...
PRETREATMENT VITAMIN D DEFICIENCY IS ASSOCIATED WITH LOWER PROGRESSION- -FREE AND OVERALL SURVIVAL IN PROSPECTIVELY TREATED HODGKIN LYMPHOMA
13 októbra, 2020 5:56 pmAuthor(s): Sven Borchmann, Helen Görgen, Stephanie Sasse, et al. Abstract: S111 Session topic: 17. Hodgkin lymphoma – Clinical...
Nedostatok vitamínu D a znížené prežívanie pacientov s Hodgkinovým lymfómom
13 októbra, 2020 5:55 pmAutori tejto práce testovali hypotézu, či znížená hladina vitamínu D znižuje prežívanie bez progresie (PFS) a celkové prežívanie (OS) pacientov s Hodgkinovým...
OUTCOMES BY NUMBER OF INDUCTION CYCLES WITH CPX-351 VERSUS 7+3 CHEMOTHERAPY IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (SAML)
13 októbra, 2020 5:55 pmAuthor(s): Jorge E. Cortes, Bruno C. Medeiros, Geoffrey L. Uy, et al. Abstract: PF239 Session topic: 4. Acute...
COMBINATION OF IDARUBICIN, CYTARABINE AND CLADRIBINE AS INDUCTION REGIMEN FOR UNTREATED ADULT AML AGED 60 OR YOUNGER: A PHASE III RANDOMIZED CLINICAL TRIAL
13 októbra, 2020 5:55 pmAuthor(s): Jia Chen, Yue Han, Chun Chen, et al. Abstract: PF228 Session topic: 4. Acute myeloid leukemia –...
ADDITION OF CRENOLANIB TO STANDARD INDUCTION AND CONSOLIDATION THERAPIES IMPROVED LONG-TERM OUTCOMES IN NEWLY DIAGNOSED FLT3-MUTANT AML PATIENTS ≤ 60 YEARS OLD
13 októbra, 2020 5:55 pmAuthor(s): Roland B. Walter, Robert H. Collins, Richard M. Stone, et al. Abstract: PF227 Session topic: 4. Acute...